Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

Liver cancer failure dents Opdivo potential by $1bn, says analyst

Adds to bad news of forced Otezla sell-off

- PMLiVE

The social dilemma: is it time for pharma to join the party?

Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun

MIT reveals new pill to deliver insulin

A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...

Blue Latitude Health

Bristol Myers Squibb logo

Faced with regulator’s merger concerns, BMS want to offload Otezla

Sell-off will mean merger delay

- PMLiVE

‘Missing protein’ biotech Stoke raises $142m in IPO

Continues pioneering research

- PMLiVE

Sanofi/Regeneron’s Dupixent successor underwhelms in phase 2

Success against placebo, but fails to outperform Dupixent

- PMLiVE

Pfizer’s Talzenna cleared for breast cancer in Europe

Fourth to market aims to carve out niche

- PMLiVE

EMA clears Novo Nordisk’s long-acting haemophilia A drug

Entering newly competitive market

- PMLiVE

England to fast-track tumour agnostic drugs like Vitrakvi – if the price is right

Simon Stevens calls for 'fair prices' from companies

Sanofi reception

Sanofi sheds jobs in R&D restructuring

New R&D chief diverting funds to new therapy areas

- PMLiVE

Mistrust of pharma still blocking NHS collaborations

Greater Manchester is leader in breaking down barriers

- PMLiVE

Merck says it has plenty in the pipe beyond Keytruda

It has the firepower, but is Merck seeking a big deal?

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links